Severe asthma is associated with the production of interleukin 17A (IL-17A). The exact role of IL-17A in severe asthma and the factors that drive its production are unknown. Here we demonstrate that IL-17A mediated severe airway hyperresponsiveness (AHR) in susceptible strains of mice by enhancing IL-13-driven responses. Mechanistically, we demonstrate that IL-17A and AHR were regulated by allergen-driven production of anaphylatoxins, as mouse strains deficient in complement factor 5 (C5) or the complement receptor C5aR mounted robust IL-17A responses, whereas mice deficient in C3aR had fewer IL-17-producing helper T cells (T H 17 cells) and less AHR after allergen challenge. The opposing effects of C3a and C5a were mediated through their reciprocal regulation of IL-23 production. These data demonstrate a critical role for complement-mediated regulation of the IL-23-T H 17 axis in severe asthma.
A r t i c l e s Recent decades have seen considerable increases in the prevalence and severity of asthma, a complex inflammatory disorder of the airways. Although the unifying pathophysiological feature of asthma is airway hyperresponsiveness (AHR) that leads to dynamic airflow obstruction, the clinical expression of this disease is heterogeneous. For example, a large percentage of patients with asthma are atopic with higher serum concentrations of immunoglobulin E (IgE), yet others have no evidence of atopy. Moreover, although the airway granulocytic infiltrate of most asthmatics is dominated by eosinophils, neutrophils dominate in patients at the severe end of the disease spectrum. At present, models suggest that asthma arises as a result of the development of aberrant T helper type 2 (T H 2) immune responses to innocuous environmental antigens in susceptible people. However, the T H 2 paradigm alone does not seem to explain the full spectrum of asthma, as severe disease is not associated with an exclusive bias toward the production of T H 2 cytokines 1-3 . Thus, additional factors beyond T H 2 cytokines probably have a role in the disease pathogenesis, which emphasizes the need for better understanding of the molecular and cellular mechanisms that underlie the diverse clinical expression of asthma to improve disease management and develop effective therapeutics.
Given that people with severe asthma have not only severe AHR but also robust neutrophilia and more production of interleukin 17A (IL-17A) [1] [2] [3] , it has been postulated that aberrant IL-17A production may drive severe forms of this disease. However, the role of IL-17A in severe asthma and the factors that drive the production of IL-17A in susceptible people are not well understood. Studies of the role of IL-17A in experimental mouse models of asthma have yielded variable results. Some studies suggest that IL-17A drives more neutrophil recruitment and AHR 4 , whereas others report that IL-17A has no role in ovalbumin-induced AHR or airway inflammation 5 . Finally, IL-17A has been reported to have either a deleterious role or a protective role depending on whether IL-17A was present during sensitization or challenge, respectively 6 . The mechanisms that underlie the variable results obtained in these studies are unknown.
To determine the factors that drive aberrant IL-17A production and the subsequent development of the severe asthma phenotype, we used a well-characterized mouse model of differences in susceptibility to severe asthma. Our data suggest that a strain of mice that develops severe AHR (A/J mice) produced both IL-17A and T H 2 cytokines, whereas a strain that manifests less severe AHR (C3H/HeJ mice) produced only T H 2 cytokines and little to no IL-17A. Blockade of IL-17A in susceptible (A/J) mice decreased the severity AHR, whereas reconstitution of IL-17A in C3H/HeJ mice exacerbated AHR. Consistent with the widely acknowledged importance of T H 2 cytokines in driving the development of allergen-induced AHR, IL-17A alone was unable to induce AHR. However, the simultaneous production of IL-17A and T H 2 cytokines exacerbated T H 2-driven pathology, which led to more severe disease. Mechanistically, the production of IL-17A and development of robust AHR was reciprocally regulated by anaphylatoxins, with signaling by complement factor C5a limiting the frequency of IL-17-producing helper T cells (T H 17 cells) and AHR, and signaling by complement factor C3a enhancing T H 17 responses and AHR. The opposing actions of C3a and C5a on IL-17A were mediated via A r t i c l e s reciprocal regulation of dendritic cell (DC) production of IL-23. The identification of a link between complement activation and the IL-23-T H 17 axis may provide insight into the underlying pathogenesis of a plethora of chronic inflammatory diseases in which IL-17A has an important pathogenic role.
RESULTS

Association of severe AHR with both IL-17A and IL-13
To determine if the development of more severe AHR in an asthmasusceptible strain of mice (A/J mice) versus the development of less severe AHR in C3H/HeJ mice was associated with differences in lung IL-17A after exposure to house dust mite allergen extract (HDM), we treated mice with HDM intratracheally on days 0 and 14, and on day 17 we measured AHR and collected lungs for analysis of cytokine concentrations by enzyme-linked immunosorbent assay (ELISA) and flow cytometry ( Supplementary Fig. 1a ). As observed before 7 , airway responses to the cholinergic agonist acetylcholine were greater in A/J mice than in C3H/HeJ mice ( Fig. 1a) . HDM-induced T H 2 cytokine concentrations were equivalent in the two strains of mice, whereas IL-17A concentrations were higher in susceptible A/J mice than in C3H/HeJ mice ( Fig. 1b) . In both strains, CD4 + cells (probably CD4 + T cells or natural killer T cells) represented the only relevant source of IL-17A (as detected by intracellular flow cytometry), and both the frequency of IL-17A + CD4 + cells ( Fig. 1c and Supplementary Fig. 2 ) and the intensity of IL-17A staining ( Fig. 1d and Supplementary Fig. 2 ) were greater after HDM. However, HDM challenge induced larger increases in the frequency of IL-17A + CD4 + cells and the intensity of IL-17A staining in susceptible A/J mice than in C3H/HeJ mice ( Fig. 1c,d) .
We found similar strain differences in the frequency of lung IL-17F + CD4 + cells ( Fig. 1e and Supplementary Fig. 2) . In contrast, the intensity of IL-17F staining was similar in both strains after HDM exposure ( Fig. 1f and Supplementary Fig. 2 ). As IL-21 and IL-22 have been noted to be 'preferentially' associated with T H 17 cells, we also assessed the frequency of IL-21 + CD4 + and IL-22 + CD4 + T cells in the lungs after HDM challenge. The frequency of both IL-21 + CD4 + and IL-22 + CD4 + cells was greater after allergen challenge in both strains of mice ( Supplementary Figs. 2 and 3) . Similar to the frequency of IL-17A + CD4 + T cells, the percentage of lung CD4 + cells expressing IL-22 was higher in A/J mice than in C3H/HeJ mice; however, the frequency of IL-21 + cells did not differ in A/J and C3H/HeJ mice. Together these data suggest that the susceptibility of A/J mice to allergeninduced AHR is correlated with a greater frequency of lung T H 17 cells expressing IL-17A, IL-17F and IL-22 in A/J mice than in the less susceptible C3H/HeJ strain.
IL-17A exacerbates allergen-induced AHR
To determine whether IL-17A enhances severity of allergen-driven AHR, we examined the effects of in vivo blockade of IL-17A by intraperitoneal injection of either isotype-matched control antibody or antibody to IL-17A (anti-IL-17A; 250 μg) into HDM-treated A/J mice by a protocol spanning sensitization and challenge periods ( Supplementary Fig. 1a ). As expected, HDM exposure induced more robust AHR than did PBS treatment ( Fig. 2a) . Mice that received anti-IL-17A had significantly less AHR than did mice that received HDM plus the control antibody. However, IL-17A blockade did not completely abrogate HDM-induced AHR, which suggested that other factors, such as T H 2 cytokines, drove the remaining AHR. The lower AHR in mice treated with anti-IL-17A was accompanied by significantly less neutrophilia in bronchoalveolar lavage (BAL) fluid with no substantial change in the number of macrophages or eosinophils ( Fig. 2b) . We found no decrease in the HDM-induced increase in the number of periodic acid-Schiff-positive airway cells after IL-17A blockade ( Fig. 2c ) or in total serum IgE titers ( Supplementary  Fig. 4 ). As reported elsewhere 8 , IL-17A blockade enhanced the production of T H 2 cytokines in HDM-restimulated lung cells in vitro ( Fig. 2d-f ). Lung cells secreted more T H 2 cytokines into the medium without the need for further HDM recall. A/J and C3H/HeJ mice produced different amounts of IL-17A but equivalent amounts of T H 2 cytokines, so we sought to determine whether exogenous delivery of recombinant mouse IL-17A during allergen challenge would enhance the responsiveness of C3H/HeJ mice. Indeed, coexposure to recombinant mouse IL-17A and HDM during the final allergen challenge ( Supplementary Fig. 1b ) rendered C3H/HeJ mice more susceptible to HDM-induced AHR (Fig. 2g) . Collectively, these data suggest that IL-17A has a pathogenic role in asthma, enhancing the severity of allergen-induced AHR.
Synergistic induction of AHR by IL-17A and IL-13
To define the individual contributions of IL-17A and IL-13 to the development of AHR, we examined the effects of airway administration of recombinant IL-17A or IL-13 (5 μg each) or a combination of both on AHR in A/J mice ( Supplementary Fig. 1c ). Similar to published findings 9,10 , we found that IL-13 induced more AHR, whereas IL-17A alone had no effect ( Fig. 3a) . Treatment with both IL-17A and IL-13 induced a significantly greater increase in AHR than did IL-13 alone, which suggests that these two cytokines work synergistically to enhance AHR. Thus, the production of both of these cytokines in A/J mice may explain their profound susceptibility to AHR.
To gain insight into the mechanisms underlying the synergy between IL-17A and IL-13, we evaluated expression of the IL-13 receptor subunits IL-4Rα and IL-13Rα1 (CD213a1) in whole lungs from mice after cytokine treatment ( Fig. 3b-d) . Neither IL-13 nor IL-17A altered the expression of Il4ra or Il13ra1. IL-13 significantly upregulated Il13ra2 expression, whereas IL-17A had no effect. The presence of IL-17A synergistically enhanced the IL-13-driven Il13ra2 expression. Similarly, we observed a synergistic enhancement of the expression of several genes typically induced by IL-13 (Tff2, Arg1 and C3) when IL-17A was also present ( Fig. 3e-g) . In contrast, IL-13 was inhibitory to the expression of the downstream IL-17A target gene Cebpb (which encodes the transcription factor C/EBP-β; Fig. 3h ). Thus, the combination of IL-17A and IL-13 may lead to the enhancement of downstream IL-13 signals and suppression of IL-17A-driven genes.
Greater IL-17A responsiveness in A/J mice To determine whether the susceptibility of A/J mice may also be due to altered sensitivity to stimulation of the IL-17 receptor (IL-17R), we compared IL-17A responsiveness in A/J and C3H/HeJ mice by treating lung cells from naive A/J and C3H/HeJ mice with IL-17A and assessing phosphorylation of the kinases Erk1 and Erk2, key IL-17A signaling intermediates 11, 12 . We observed phosphorylation of Erk1 and Erk2 in CD11b + cells after stimulation with IL-17A in both strains. A/J cells were more sensitive to IL-17A and showed more phosphorylation of Erk1 and Erk2 than did cells from C3H/HeJ mice ( Fig. 4a ). In addition, IL-17A induced higher expression of costimulatory molecules and major histocompatibility complex class II on bone marrow-derived DCs (BMDCs) from A/J mice than on BMDCs from C3H/HeJ mice ( Fig. 4b) .
To demonstrate that the enhanced responsiveness was not limited to hematopoietic cells, we showed that expression of the IL-17A-responsive genes Cebpd, Cebpb and Cxcl1, which encode factors downstream of IL-17A, as well as the abundance of chemokine CXCL1 protein, were greater in A/J lung fibroblasts treated with recombinant IL-17A than in C3H/HeJ lung fibroblasts treated with recombinant IL-17A ( Fig. 4c-f ). To determine whether the greater responsiveness of A/J cells to IL-17A was due to larger amounts of the IL-17A receptor (IL-17RA), we measured the abundance of Il17ra mRNA in BMDCs and lung fibroblasts from both strains. We found that A/J cells expressed more Il17ra than did A r t i c l e s C3H/HeJ cells ( Fig. 4g) . Collectively, our findings suggest that excess IL-17A production in A/J mice is compounded by an enhanced sensitivity to IL-17A.
Link between genetic deficiency in C5 or IL-17A and AHR To identify potential mechanisms responsible for the differences in IL-17A production by A/J and C3H/HeJ mice, we focused on known genetic differences between the two strains. C3H/HeJ mice have a natural mutation in the gene encoding Toll-like receptor 4 (Tlr4) that renders them unresponsive to lipopolysaccharide 13 . However, the failure of C3H/HeJ mice to develop either AHR or an IL-17A response was not a result of defective lipopolysaccharide signaling, as their Tlr4-sufficient congenic strain C3H/HeN showed similarly lower production of AHR and IL-17A ( Supplementary Fig. 5 ). This result is consistent with a published report demonstrating that the Tlr4 genotype does not correlate with airway responses in (A/J × C3H/HeJ) F 1 × A/J-backcrossed mice 14 .
A/J mice also have a two-base pair deletion in the gene encoding C5 that results in the production of a nonfunctional protein 15 , and C5 deficiency of A/J mice is associated with allergen-driven AHR 14 . To examine the association between C5a and IL-17A more broadly, we measured the serum concentration of C5a and frequency of T H 17 cells in the lungs of several commonly used mouse strains. We observed a linear inverse relationship between absolute amount of serum C5a and the frequency of T H 17 cells in the lungs (r 2 = 0.6915; P = 0.0105) and IL-17A staining intensity (r 2 = 0.8525; P = 0.0011) after HDM challenge (Fig. 5a,b) . In contrast, we observed no correlation between serum C5a concentration and the frequency of lung CD4 + IL-13 + or CD4 + Foxp3 + cells (data not shown).
To directly demonstrate that C5 deficiency has a role in IL-17A regulation and the development of severe AHR, we blocked C5aR in the commonly used C5-sufficient BALB/c mice with a monoclonal antibody (mAb) to C5aR or an isotype-matched control mAb 24 h before each HDM exposure. When C5aR was blocked, we observed significantly more exacerbation of AHR than that in HDM-exposed mice treated with isotype-matched control mAb, and IL-17A blockade completely reversed the enhancement of AHR in mice treated with anti-C5aR (Fig. 5c) . Furthermore, we found that blockade of the C5aR pathway resulted in more lung T H 17 cells (Fig. 5d) . Notably, unlike HDM challenge in C5-deficient A/J mice, HDM challenge in C5-sufficient BALB/c mice induced few CD4 + IL-17A + cells ( Fig. 5a,b,d) , and therefore IL-17A blockade alone had no effect on HDM-induced AHR in the absence of C5aR blockade (Fig. 5c ). In confirmation of those findings, we found that the influx of T H 17 cells into the lungs after HDM treatment was greater in mice deficient in the gene encoding C5aR (C5ar1) on a BALB/c background than in their wildtype controls (Supplementary Fig. 6a ) and that they produced more IL-17A per cell (Supplementary Fig. 6b) , similar to the association of C5 deficiency and HDM-induced increases in pulmonary CD4 + IL-17A + cells observed in A/J mice. These results demonstrate that regardless of the overall genetic background, the concentration of C5a is associated with IL-17A production in the lung after allergen exposure and with susceptibility to the development of allergeninduced AHR in mice.
To delineate the mechanism by which C5a regulates IL-17A production, we examined the production of DC cytokines (IL-6, IL-1β and IL-23) known to drive the differentiation and proliferation of T H 17 cells. We found that BMDCs from C5ar1-deficient mice produced more HDM-driven IL-23 than did BMDCs from wild-type BALB/c control mice (Fig. 5e) , with no significant difference in the concentration of IL-6 and IL-1β ( Fig. 5f,g) . Similarly, we found that BMDCs from A/J mice produced more IL-23 than did those from C3H/HeJ mice, whereas we found only small differences in the production of IL-6 and IL-1β ( Fig. 5h-j) . Together these results suggest that C5a signaling controls IL-17A by limiting IL-23 production.
Promotion of DC IL-23 production by C3 signaling It has been shown that C5a and C3a have reciprocal roles in the regulation of allergic inflammation 16 . Thus, to determine whether C3a has an effect on the IL-23-T H 17 axis, we determined whether C3a altered DC production of IL-23 by comparing the effects of HDM on IL-23 production in mice deficient in the gene encoding the complement receptor C3aR (C3ar1) and their BALB/c wild-type controls. Lack of C3aR signaling resulted in less HDM-induced production of IL-23 ( Fig. 6a) and IL-6 ( Fig. 6b) . In contrast, HDM-induced secretion of IL-1β was enhanced in C3ar1-deficient cells (Fig. 6c) . C3ar1-deficient mice had less induction of AHR, fewer CD4 + IL17A + T cells in the lung and lower IL-17A signaling intensity than did BALB/c wild-type mice (Fig. 6d-f) . We next examined the kinetics of complement expression after allergen exposure in A/J and C3H/HeJ mice. We found that HDM enhanced C3 and C3ar1 mRNA in the lungs of both strains, but it did so to a greater extent in C5-deficient A/J mice (Fig. 6g,h) . A r t i c l e s Collectively, these results suggest that C3a mediates the production of IL-23 and IL-17A and susceptibility to AHR, whereas C5a production suppresses DC production of IL-23 and IL-17A, which limits the magnitude of allergen-driven AHR.
Positive feedback regulation of C3-C3aR by IL-17A
As it has been shown that IL-17A induces C3 expression in skin fibroblasts 17 , we determined whether IL-17A induced C3 production in A/J lung cells. We found that IL-17A induced C3 expression in mouse tracheal epithelial cells and that C3 production was greater in cells from A/J mice than in cells from C3H/HeJ mice (Fig. 7a) .
To confirm that IL-17A similarly enhances the generation of the anaphylotoxin C3a (the relevant cleavage product of C3) in vivo, we measured the concentration of C3a in BAL fluid from A/J mice treated with HDM after IL-17A blockade. We found that the concentration of C3a was greater after allergen challenge and was lower after IL-17A blockade (Fig. 7b) . In addition, in vitro treatment of BMDCs with IL-17A also induced C3a (Fig. 7c) , and intratracheal administration of recombinant IL-17A to A/J mice led to more C3a in BAL fluid (Fig. 7d) . Together these findings suggest that IL-17A induces its own production through a positive feedback mechanism that involves production of C3 by IL-17A, which in turn drives greater DC IL-23, leading to further IL-17A production by T H 17 cells.
Complement regulation of IL-23 is IL-10 dependent
To delineate the mechanisms by which C5a and C3a regulate IL-23 production, we explored the possibility that IL-10 was responsible for C5a-mediated inhibition of IL-23 production. HDM alone induced IL-10 production in BMDCs from BALB/c mice, and the addition of C5a enhanced IL-10 production, whereas C3a inhibited IL-10 secretion ( Fig. 8a) . Blocking IL-10 in HDM-stimulated cultures enhanced IL-23 production (Fig. 8b) , which suggests that IL-10 negatively regulates IL-23 production. Moreover, blockade of IL-10 in cultures stimulated with HDM plus C5a completely abrogated the ability of C5a to limit IL-23 production, which suggests that IL-10 is critical for C5a-mediated inhibition of IL-23 production.
To identify the intracellular signaling pathways through which HDM and C5a regulate the production of IL-23, we stimulated DCs with HDM or with HDM plus C5a in the presence of inhibitors of a variety of signaling pathways. Treatment of DCs with the c-Jun N-terminal kinase (Jnk) inhibitor SP600125 did not affect HDM-induced IL-23 production, whereas treatment with AS602868, a specific inhibitor of IKK2 (the IκB (inhibitor of transcription factor NF-κB) kinase) 18 , completely abrogated IL-23 production (Fig. 8c) , which suggested that NF-κB was absolutely required for allergen-induced IL-23. In addition, like the previously identified inhibitory role for the kinase mTOR in regulating lipopolysaccharide-induced IL-23 production 19 , we found that inhibition of mTOR signaling with rapamycin enhanced HDM-induced IL-23 (Fig. 8c) . In contrast, blockade of Jnk signaling completely abrogated the effect of C5a on IL-23 production, whereas inhibition of either NF-κB or mTOR had no effect (Fig. 8c) . This finding suggests that Jnk is a critical mediator by which C5a regulates HDM-induced IL-23 production in DCs. Consistent with the idea of an important role for IL-10 in the ability of C5a to limit IL-23 production, blockade of Jnk resulted in less IL-10 production by DCs induced by either C5a plus HDM or HDM alone (Fig. 8d) , whereas rapamycin resulted in less production of IL-10 ( Fig. 8d) , which further supports the idea of a role for IL-10 in the negative regulation of IL-23. Additionally, stimulation of RAW264.7 mouse macrophage cells for 30 min with recombinant C5a induced phosphorylation of c-Jun at Ser63 (Fig. 8e) , which suggests that C5a can directly activate that pathway.
Jnk can activate several downstream molecules, including c-Jun, a canonical component of the transcription factor AP-1. Thus, to test the importance of AP-1 in C5a-mediated inhibition of HDM-stimulated IL-23 production, we transfected RAW264.7 macrophages with an AP-1 reporter construct and observed that although AP-1 activity was not affected by HDM alone, AP-1 activity was ~25% greater in the presence of C5a, and this effect was abolished by blockade of Jnk with SP600125 ( Fig. 8f) . Demonstrating a role for C5a-induced IL-10 in regulating AP-1, cells that received HDM plus C5a in the presence of anti-IL-10 had less AP-1 activity than did cells treated in the presence of a control IgG1 antibody, whereas the addition of recombinant IL-10 to HDM-treated cells also resulted in upregulation of AP-1 (Fig. 8g) . To conclusively show that AP-1 activity decreases IL-23 expression, we transfected RAW264.7 macrophages with an A/J Il23a promoter fragment fused to luciferase and observed that HDM-induced Il23a promoter activity was much lower after overexpression of the canonical AP-1 components c-Jun and c-Fos (Fig. 8h) .
To confirm that these AP-1 components were expressed differently in C5-deficient A/J BMDCs and C5-sufficient C3H/HeJ BMDCs, we assessed Jun and Fos messages and found that Jun mRNA was more abundant in the C5-sufficient strain than in the C5-deficient A/J mice (Fig. 8i) . Together these data show the critical importance of C5ainduced IL-10 in regulating IL-23 output from DCs and the central role of AP-1 in mediating this effect.
DISCUSSION
Although asthma has long been thought to be a T H 2-driven disease, studies suggest that higher expression of pulmonary T H 17 cytokines 1-3 is correlated with greater airway hyperresponsiveness 3 and disease severity in humans 1, 2 . Despite the association between T H 17 cytokines and severe asthma, very little is known about the regulation of T H 17 cytokine production in asthma or the mechanisms by which T H 17 cytokines drive severe disease. Consistent with the role of T H 17 cytokines in human disease, we found that susceptibility to severe AHR was associated with more production of T H 17-associated cytokines (IL-17A, IL-17F and IL-22), whereas mild AHR was associated with abundant production of T H 2 cytokines but little to no production of T H 17 cytokines. We have shown that IL-17A drove the severe phenotype, as blockade of IL-17A resulted in less AHR in susceptible mice, whereas reconstitution in resistant strains enhanced AHR. Although the mechanisms responsible for the IL-17A-mediated exacerbation of AHR are unclear, the lower AHR after IL-17A blockade was associated with fewer neutrophils in BAL fluid. Although neutrophils probably have a role in driving asthma severity, it has been shown that although they contribute to AHR, they are not sufficient to drive AHR 20 . Our observation that administration of IL-17A alone did not induce airway responses supports that idea. These findings are consistent with the much greater airway neutrophilia in severe asthma patients and in those undergoing acute severe exacerbations [21] [22] [23] . Although it has been noted before that T H 17 cells and T H 2 cells may be directly antagonistic 24, 25 , we observed that the dominant effect of IL-17A in vivo in promoting severe AHR occurred through enhancement of IL-13 signaling not in T cells but in downstream effector cells (smooth muscle and fibroblasts) 20, 26, 27 . Thus, our data demonstrate that excessive IL-17A production drives the severe asthma phenotype by enhancing T H 2 cell-driven pathology.
As the gene encoding C5 has been identified as a susceptibility gene for asthma 19 , we explored the possibility that alterations in this gene may underlie excessive T H 17 production in susceptible strains of mice. Here we have reported a previously unrecognized role for C5 in the regulation of T H 17 cell-mediated immune responses and severe asthma. We have demonstrated a direct link among C5aR signaling, IL-17A production and severe AHR, in that the enhancement of AHR severity noted in mice after C5aR blockade was completely reversed by coincident IL-17A blockade. Notably, the inverse association between C5 and T H 17 cytokines held up across a wide spectrum of mouse strains. These findings provide a mechanistic explanation for the long-unexplained observation that C5 provides protection against the development of AHR 14, 28, 29 and support the general tenet that the complement system has an important immunoregulatory role at the interface of innate immunity and acquired immunity.
Although several factors have been shown to be important in T H 17 differentiation, our data demonstrated that C5a regulated T H 17 cytokine production through specific regulation of IL-23 production, as it did not affect the production of other T H 17-promoting cytokines in the context of allergen exposure (IL-6, IL-1β and transforming growth factor-β). The regulation of IL-23 by C5aR signaling occurred through Jnk-dependent induction of IL-10 production. IL-10 in turn increased AP-1 activation (c-Jun and c-Fos) that directly limited Il23a promoter activity. The ability of C5a to stimulate IL-10 production probably explains its ability to suppress IL-12p70 (refs. 30,31) and IL-23p19 and thus T H 1 and T H 17 responses, respectively, and supports our general tenet that C5a regulates the maintenance of tolerance at the mucosal surface.
Consistent with a published report showing that C5a and C3a reciprocally regulate several features of the adaptive immune response 17 , we have demonstrated here that in contrast to C5a, C3a promoted AHR, IL-23 production and T H 17 responses by suppressing IL-10 synthesis by DCs. Consistent with a proallergic role for C3a, several triggers of asthma (HDM, cigarette smoke, viruses and pollutants) both activate C3 (refs. [32] [33] [34] [35] [36] and drive AHR in a C3-dependent manner in mouse models. These findings are relevant to human disease, as higher plasma concentrations of C3a have been found in people experiencing acute asthma exacerbations, more so in patients who require hospitalization than those who do not 37 . Moreover, polymorphisms in C3 and C3ar1 are positively associated with human asthma 38, 39 . In contrast, polymorphisms in the gene encoding C5 have been associated with protection from asthma in humans 39 . Collectively, these studies suggest that C5, normally present at the mucosal surface, has a role in maintaining a tolerogenic environment through the promotion of IL-10 production. After exposure to allergenic triggers, C3 is activated and shifts the balance toward the activation of the IL-23-T H 17 axis, driving more severe AHR. Once produced, IL-17A, alone or synergistically with IL-13, initiates an amplification loop by directly inducing more C3 production by pulmonary cells, enhancing IL-23 production and thereby perpetuating the response.
We have ruled out the possibility of a role for the traditional TLR pathway in the regulation of IL-17A and AHR in our model, in that mice of the Tlr4-deficient (C3H/HeJ) strain and those of its Tlr4sufficient congenic (C3H/HeN) strain both developed less severe AHR and produced small amounts of IL-17A after HDM exposure. Although TLR pathways may have important roles in driving T H 2 responses and milder AHR responses 40, 41 , they do not seem to be important in regulating the T H 17 response to allergen exposure.
In summary, we have demonstrated here that the severe asthma phenotype is driven by dysregulated anaphylatoxin control of the IL-23-T H 17 axis, which leads to excessive IL-17A production. This aberrant T H 17 response occurs as a result of a shift from C5a-driven tolerance toward C3a-driven T H 17 responses at the airway surface. Disruption of this delicate balance may occur as a result of either genetic alterations in complement genes or activation of the C3a pathway by environmental triggers of asthma. As severe forms of asthma have proven difficult to treat with existing therapies, modulation of anaphylatoxins may hold promise for the treatment of this everincreasing disease. Our findings have implications beyond the context of asthma, as in both mice and humans, the dysregulation of complement pathways has been linked to a plethora of chronic inflammatory human diseases in which IL-17A has an important role [42] [43] [44] [45] .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
